Compounds exhibiting X-type sPLA 2 inhibiting effect

Details Compounds exhibiting X-type sPLA 2 inhibiting effect Compounds exhibiting X-type sPLA 2 inhibiting effect

2006-04-11

2006-04-11

Tucker, Zachary C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S349000

Reexamination Certificate

active

07026318

ABSTRACT:
A compound represented by the general formula:wherein R20is —CH2COOH and the like; R21is —COCONH2and the like; R22is C4–C6 alkyl; and the like; R23is —CH2—R18wherein R18is aryl and the like; R24is hydrogen or C1–C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable salt, or a solvate having type X sPLA2inhibitory effect was found.

REFERENCES:
patent: 2 346 334 (2000-04-01), None
patent: 0 620 214 (1994-10-01), None
patent: 0 620 215 (1994-10-01), None
patent: 0 675 110 (1995-10-01), None
patent: 0 987 250 (2000-03-01), None
patent: 1 085 021 (2001-03-01), None
patent: 1 157 704 (2001-11-01), None
patent: 96/03120 (1996-02-01), None
patent: 96/03376 (1996-02-01), None
patent: 96/03383 (1996-02-01), None
patent: 97/21664 (1997-06-01), None
patent: 97/21716 (1997-06-01), None
patent: 98/18464 (1998-05-01), None
patent: 98/24437 (1998-06-01), None
patent: 98/24756 (1998-06-01), None
patent: 98/24794 (1998-06-01), None
patent: 98/25609 (1998-06-01), None
patent: 98/37069 (1998-08-01), None
patent: 99/09978 (1999-03-01), None
patent: 99/16453 (1999-04-01), None
patent: 99/25339 (1999-05-01), None
patent: 99/51605 (1999-10-01), None
patent: 99/57100 (1999-11-01), None
patent: 00/00201 (2000-01-01), None
patent: 00/21563 (2000-04-01), None
patent: 01/26653 (2001-04-01), None
Blanchard et al, “Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2” Pharmaceutical Biotechnology, vol. 11, pp. 445-463 (1998).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
S. Hagishita et al., “Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives”, J. Med. Chem., vol. 39, pp. 3636-3658, 1996.
K. Watanabe et al., “Role of the Prostaglandin E Receptor Subtype EP1in Colon Carcinogenesis1”, Cancer Research, vol. 59, pp. 5093-5096, 1999.

Affiliated with

Also associated with

Rating

Compounds exhibiting X-type sPLA 2 inhibiting effect does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds exhibiting X-type sPLA 2 inhibiting effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds exhibiting X-type sPLA 2 inhibiting effect will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3617427